IRADIMED CORPORATION

NasdaqCM:IRMD Stock Report

Market Cap: US$536.5m

IRADIMED Dividend

Dividend criteria checks 3/6

IRADIMED is a dividend paying company with a current yield of 5.08% that is well covered by earnings.

Key information

5.1%

Dividend yield

11%

Payout ratio

Industry average yield1.8%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Earnings per shareUS$1.36
Dividend yield forecast in 3Yn/a

Recent dividend updates

Recent updates

If EPS Growth Is Important To You, IRadimed (NASDAQ:IRMD) Presents An Opportunity

Feb 23
If EPS Growth Is Important To You, IRadimed (NASDAQ:IRMD) Presents An Opportunity

Getting In Cheap On IRadimed Corporation (NASDAQ:IRMD) Is Unlikely

Feb 07
Getting In Cheap On IRadimed Corporation (NASDAQ:IRMD) Is Unlikely

Should You Investigate IRadimed Corporation (NASDAQ:IRMD) At US$45.06?

Nov 06
Should You Investigate IRadimed Corporation (NASDAQ:IRMD) At US$45.06?

Calculating The Intrinsic Value Of IRadimed Corporation (NASDAQ:IRMD)

Oct 13
Calculating The Intrinsic Value Of IRadimed Corporation (NASDAQ:IRMD)

At US$41.26, Is It Time To Put IRadimed Corporation (NASDAQ:IRMD) On Your Watch List?

Feb 05
At US$41.26, Is It Time To Put IRadimed Corporation (NASDAQ:IRMD) On Your Watch List?

Iradimed withdraws FDA filing for new infusion pump; prelim Q3 revenue rises 13% Y/Y

Oct 10

IRadimed: Record Revenue Could Translate To Share Price Appreciation

Aug 23

Here's Why We Think IRadimed (NASDAQ:IRMD) Is Well Worth Watching

Aug 17
Here's Why We Think IRadimed (NASDAQ:IRMD) Is Well Worth Watching

iRadimed Non-GAAP EPS of $0.26 beats by $0.02, revenue of $12.7M beats by $0.06M

Jul 29

IRadimed: Reduce Equity Beta With Upside Capture

Jul 18

IRadimed (NASDAQ:IRMD) Might Be Having Difficulty Using Its Capital Effectively

Jul 13
IRadimed (NASDAQ:IRMD) Might Be Having Difficulty Using Its Capital Effectively

At US$48.60, Is IRadimed Corporation (NASDAQ:IRMD) Worth Looking At Closely?

Feb 05
At US$48.60, Is IRadimed Corporation (NASDAQ:IRMD) Worth Looking At Closely?

Here's What's Concerning About IRadimed's (NASDAQ:IRMD) Returns On Capital

Jan 12
Here's What's Concerning About IRadimed's (NASDAQ:IRMD) Returns On Capital

Returns On Capital At IRadimed (NASDAQ:IRMD) Paint A Concerning Picture

Jul 13
Returns On Capital At IRadimed (NASDAQ:IRMD) Paint A Concerning Picture

iRadimed EPS beats by $0.04, beats on revenue

Apr 30

iRadimed EPS misses by $0.02, beats on revenue

Feb 04

If You Had Bought IRadimed (NASDAQ:IRMD) Stock Five Years Ago, You Could Pocket A 70% Gain Today

Jan 31
If You Had Bought IRadimed (NASDAQ:IRMD) Stock Five Years Ago, You Could Pocket A 70% Gain Today

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Too early to tell whether IRMD's dividend payments have been stable as they only just started paying a dividend.

Growing Dividend: Too early to tell if IRMD's dividend payments are increasing as they only just started paying a dividend.


Dividend Yield vs Market

IRADIMED Dividend Yield vs Market
How does IRMD dividend yield compare to the market?
SegmentDividend Yield
Company (IRMD)5.1%
Market Bottom 25% (US)1.6%
Market Top 25% (US)4.8%
Industry Average (Medical Equipment)1.8%
Analyst forecast in 3 Years (IRMD)n/a

Notable Dividend: IRMD's dividend (5.08%) is higher than the bottom 25% of dividend payers in the US market (1.58%).

High Dividend: IRMD's dividend (5.08%) is in the top 25% of dividend payers in the US market (4.8%)


Earnings Payout to Shareholders

Earnings Coverage: With its low payout ratio (11%), IRMD's dividend payments are thoroughly covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its high cash payout ratio (494.2%), IRMD's dividend payments are not well covered by cash flows.


Discover strong dividend paying companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.